; (B) best practices and recommendations for institutional review boards related to the inclusion of pregnant and lactating women in clinical research, including information on successes and challenges of using a centralized institutional review board; and (C) an evaluation of statutory programs enacted to spur pediatric-specific information in Food and Drug Administration-approved therapies, such as the Best Pharmaceuticals for Children Act ( Public Law 107–109 ) and the Pediatric Research Equity Act of 2008 ( Public Law 108–155 ), and how approaches taken in such programs can be applied to clinical research including pregnant and lactating women. (3) Public availability The Secretary shall make the report required by paragraph (1) available on a public website of the Department of Health and Human Services. (h) Termination (1) In general The Committee shall terminate on the date that is 5 years after the date on which the Committee is established under subsection (a). (2) Extension The Secretary may extend the operation of the Committee for up to 3 additional 2-year periods following the 5-year period described in paragraph (1) if the Secretary determines that the extension is appropriate to monitor the implementation of the recommendations and implementation plan described in subsection (b)(3) or any additional recommendations made by the Committee. 5. Raising awareness of research that includes pregnant and lactating women in clinical research (a) In general The Secretary, acting through the Director of the National Institutes of Health, in consultation with the heads of other relevant Federal agencies, shall establish and implement an education campaign designed to— (1) educate the public on the importance of— (A) including pregnant and lactating women in clinical research to better inform health care decisions on the safety and effectiveness of medications for pregnant and lactating women before, during, and after pregnancy; (B) registries and clinical trials that include pregnant and lactating women